---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-057137"
form_type: "8-K/A"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:05:15.532053+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# ABVC BioPharma gets Nasdaq extension to comply with equity rule; deadline August 31, 2023

## Summary
- Received deficiency letter on May 26, 2023 for non-compliance with minimum stockholders' equity requirement.
- Nasdaq granted extension on July 10, 2023 to comply with Listing Rule 5550(b)(1) by August 31, 2023.
- Failure to evidence compliance upon filing Q3 2023 periodic report may lead to delisting from Nasdaq.
- Common stock continues trading under symbol ABVC on Nasdaq Capital Market while appeal rights exist.

## SEC filing metadata
- accession: 0001213900-23-057137
- form_type: 8-K/A
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023057137/0001213900-23-057137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023057137/ea181759-8ka1_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-057137
- JSON: https://secwatch.observer/filing/0001213900-23-057137.json
- Plain text: https://secwatch.observer/filing/0001213900-23-057137.txt

## Key facts
- Listing & Compliance Notices
  ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: July 10, 2023,Nasdaq granted the Company an extension to comply with Listing Rule 5550(b)(1). The Company must now achieve compliance with this rule on or before August 31, 2023. If the Company fails to evidence compliance upon filing its periodic report for the quarter ending September 30, 2023, the Company may be subject to delisting. If Nasdaq determines to delist the Company’s securities, the Company will have an opportunity to appeal Nasdaq’s decision. At this time, the Company’s Common Stock will continue to trade on The Nasdaq Capital Market under the symbol “ABVC”. SIGNATURE Pursuant t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023057137/0001213900-23-057137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.